Godavari Drugs reported a year-on-year rise in Q1 FY27 revenue and net profit, but a sequential decline. The company also saw promoters convert warrants, increasing its equity share capital.
Godavari Drugs Q1 FY27 Results: Revenue Up YoY, Profit Declines Sequentially; Promoters Convert Warrants
Revenue from operations stood at Rs 27.96 crore for the quarter ended June 30, 2026, an increase from Rs 23.81 crore a year ago. Net profit for the same period was Rs 1.11 crore, up from Rs 1.04 crore in the corresponding quarter last year. Reader Takeaway: Year-on-year growth is positive, but sequential moderation and promoter warrant conversion warrant attention. ## What just happened Godavari Drugs Ltd announced its financial results for the first quarter of fiscal year 2027 (ended June 30, 2026). The company reported consolidated revenue from operations of Rs 27.96 crore, a 17.4% increase compared to Rs 23.81 crore in the same quarter of the previous fiscal year. Net profit for Q1 FY27 rose to Rs 1.11 crore, a 6.7% improvement from Rs 1.04 crore in Q1 FY26. However, on a sequential basis, revenue decreased from Rs 33.16 crore in Q4 FY26, and net profit declined from Rs 1.29 crore in the preceding quarter. The company also informed the stock exchanges about the allotment of 7,86,690 equity shares to the promoter category following the conversion of warrants. These shares were issued at a price of Rs 89 per share, reflecting the balance 75% of the issue price received from the allottees. This corporate action has increased the company's paid-up equity share capital to Rs 10.91 crore from Rs 10.13 crore. Furthermore, Godavari Drugs confirmed that there has been no deviation in the utilization of funds raised through preferential issues. ## Why this matters The year-on-year growth in revenue and profit indicates improving business traction. The conversion of warrants by promoters signals their confidence and increased stake in the company, which can be viewed positively by investors. However, the sequential dip in performance might raise concerns about short-term business momentum and need for further scrutiny. ## The backstory Godavari Drugs is primarily engaged in the manufacturing of pharmaceutical formulations and active pharmaceutical ingredients (APIs). The company has been working on expanding its product portfolio and market reach. ## What changes now The conversion of warrants increases the company's equity base, potentially strengthening its balance sheet. Investors will now track the company's ability to sustain and improve its performance in upcoming quarters, especially in light of the sequential moderation observed in the current results. ## Risks to watch Any potential slowdown in the pharmaceutical sector, increased competition, or challenges in raw material sourcing could impact Godavari Drugs' future performance. The sequential decline in revenue and profit needs to be closely monitored to understand the underlying reasons and their potential impact. ## Peer comparison {Peer comparison data unavailable in the filing.} ## Context metrics (time-bound) * **Q1 FY27 Revenue:** Rs 27.96 crore (YoY growth of 17.4% from Rs 23.81 crore in Q1 FY26) * **Q1 FY27 Net Profit:** Rs 1.11 crore (YoY growth of 6.7% from Rs 1.04 crore in Q1 FY26) * **Share Allotment:** 7,86,690 equity shares issued at Rs 89 per share. * **Paid-up Capital Increase:** From Rs 10.13 crore to Rs 10.91 crore. ## What to track next Investors should focus on the company's management commentary for the upcoming earnings calls to understand the reasons behind the sequential performance moderation and the outlook for future growth. Monitoring market share, new product launches, and any further corporate actions will also be crucial.
